Furthermore, along with hormonal therapy, current treatments for HER2-positive breast cancer include trastuzumab (a monoclonal antibody) and lapatinib (a tyrosine kinase inhibitor); however, they exhibit many limitations, mainly cardiac complications and chemo-resistance [5], [6], [7], [8], [9]. Here, ERBB2 is linked to breast carcinoma.